{"id":57536,"date":"2024-02-27T17:49:12","date_gmt":"2024-02-27T17:49:12","guid":{"rendered":"https:\/\/medsname.com\/hqcheal\/"},"modified":"2026-04-30T10:24:25","modified_gmt":"2026-04-30T10:24:25","slug":"hqcheal","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/hqcheal\/","title":{"rendered":"Hqcheal"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8d6;border-left:4px solid #f5c518;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">Gyors v\u00e1lasz<\/h3>\n<p><strong>Hqcheal<\/strong> tartalmaz <strong>hydroxychloroquine sulfate<\/strong> 200 mg (Healing Pharma). It treats and prevents <strong>chloroquine-sensitive malaria<\/strong>, and is the first-line aminoquinoline for <strong>rheumatoid arthritis<\/strong>, <strong>systemic lupus erythematosus<\/strong>, <strong>discoid lupus<\/strong>, \u00e9s <strong>Sj\u00f6gren&#8217;s syndrome<\/strong>. Dose: 400 mg\/day for autoimmune disease (long-term maintenance \u2264 5 mg\/kg\/day actual body weight); 800 mg loading then 400 mg at 6 \/ 24 \/ 48 h for acute uncomplicated chloroquine-sensitive malaria. <strong>Mandatory baseline + annual ophthalmology screening<\/strong> after 5 years of continuous use to detect retinopathy. Modern endemic areas (sub-Saharan Africa, India, Southeast Asia, Amazon) have widespread chloroquine resistance \u2014 hydroxychloroquine is NOT the right prophylaxis for those destinations. Take with food to reduce GI upset.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f4f4;border:1px solid #e0e0e0;border-radius:6px;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.5;\"><strong>\ud83c\udfed WHO-GMP tan\u00fas\u00edtott gy\u00e1rt\u00f3<\/strong> &nbsp;\u00b7&nbsp; <strong>\ud83d\udce6 Diszkr\u00e9t csomagol\u00e1s<\/strong> &nbsp;\u00b7&nbsp; <strong>\ud83c\udf0d Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s<\/strong> &nbsp;\u00b7&nbsp; <strong>\u2b50 <a href=\"https:\/\/medsbase.com\/hu\/reviews\/\">1,400+ v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a><\/strong><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:13px;color:#555;margin:10px 0 18px;\">\ud83d\udee1\ufe0f Every order is covered by our <a href=\"https:\/\/medsbase.com\/hu\/medsbase-re-shipment-assurance-policy\/\"><strong>\u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n<h3>Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n<p>Hqcheal is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our <a href=\"https:\/\/medsbase.com\/hu\/medsbase-re-shipment-assurance-policy\/\">\u00dajrak\u00fcld\u00e9si Garancia<\/a> and supported by our <a href=\"https:\/\/medsbase.com\/hu\/reviews\/\">1,400+ v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>. Worldwide shipping with no prescription paperwork.<\/p>\n<h2>About Hqcheal<\/h2>\n<p>Hqcheal is a 200 mg hydroxychloroquine sulfate tablet manufactured by Healing Pharma under WHO-GMP certified conditions. Hydroxychloroquine is a 4-aminoquinoline antimalarial that doubles as the workhorse <strong>conventional synthetic disease-modifying anti-rheumatic drug (csDMARD)<\/strong> for mild-to-moderate rheumatoid arthritis and connective-tissue disease, with the lowest toxicity profile of any DMARD when dosed correctly.<\/p>\n<h2>How hydroxychloroquine works<\/h2>\n<p>Hydroxychloroquine accumulates in the acidic lysosomes of cells. In <strong>malaria parasites<\/strong> it interferes with haemoglobin digestion in the food vacuole, allowing toxic free haem to accumulate and kill the parasite. In <strong>autoimmune disease<\/strong> the lysosomotropic effect raises lysosomal pH, which interferes with antigen processing by dendritic cells, dampens Toll-like receptor signalling (especially TLR-7 and TLR-9 which recognise self-nucleic acids), and reduces interferon-\u03b1 production. The dual mechanism explains why a single drug treats two unrelated diseases.<\/p>\n<p>Half-life is ~ 40 days (steady state 4\u20136 weeks). Effect on autoimmune disease takes 8\u201312 weeks to develop and continues to deepen over 6 months \u2014 patience and adherence matter.<\/p>\n<h2>What Agoprex is and how it works<\/h2>\n<div style=\"overflow-x:auto;margin:18px 0;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:14px;\">\n<thead>\n<tr>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Dose<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Id\u0151tartam \/ megjegyz\u00e9sek<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Rheumatoid arthritis (mild\u2013moderate)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">200\u2013400 mg\/day in 1\u20132 divided doses (max 5 mg\/kg\/day actual body weight)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Onset 8\u201312 weeks. Long-term maintenance. Often combined with methotrexate or sulfasalazine.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Systemic lupus erythematosus (SLE)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">200\u2013400 mg\/day, max 5 mg\/kg\/day<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Background therapy for almost all SLE patients per EULAR \u2014 reduces flares, organ damage, thrombosis, and improves survival.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Discoid \/ cutaneous lupus<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">200\u2013400 mg\/nap<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">First-line systemic for skin-only lupus. Can take 8\u201312 weeks for visible improvement.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Sj\u00f6gren&#8217;s syndrome<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">200\u2013400 mg\/nap<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Modest-evidence improvement in fatigue + arthralgia; little effect on dryness.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Acute uncomplicated chloroquine-sensitive P. falciparum \/ P. vivax \/ P. ovale \/ P. malariae<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">800 mg loading \u2192 400 mg at 6 h \u2192 400 mg at 24 h \u2192 400 mg at 48 h (total 2 g over 48 h)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Treatment course only \u2014 for chloroquine-sensitive areas. Add primaquine for radical cure of vivax\/ovale.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Chloroquine-sensitive malaria prophylaxis<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">400 mg once weekly<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Start 1\u20132 weeks before travel, continue weekly during exposure, continue 4 weeks after return. Limited modern utility \u2014 most destinations are resistant.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.6;\"><strong>Retinal-toxicity red-box.<\/strong> Hydroxychloroquine accumulates in retinal pigment epithelium. <strong>Risk of irreversible bull&#8217;s-eye maculopathy<\/strong> rises sharply after 5 years of continuous use, especially at doses &gt; 5 mg\/kg\/day actual body weight, with renal impairment, with concurrent tamoxifen, or in patients with pre-existing retinal disease. <strong>American Academy of Ophthalmology \/ Royal College of Ophthalmologists guidance: baseline fundus exam at start of long-term therapy + annual screening from year 5 onwards<\/strong> using spectral-domain OCT, automated visual field 10-2 (white test object), and fundus autofluorescence. Earlier screening if dose &gt; 5 mg\/kg\/day, renal CrCl &lt; 60 mL\/min, or concurrent tamoxifen. Stop the drug at the first sign of pre-toxicity \u2014 damage already established does not reverse.<\/div>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.6;\"><strong>G6PD note.<\/strong> Hydroxychloroquine has a much smaller G6PD-haemolysis signal than primaquine, but case reports exist in severe G6PD deficiency. If G6PD status is unknown, monitor for haemolysis (dark urine, pallor, fatigue) in the first weeks of high-dose therapy.<\/div>\n<h2>Monitoroz\u00e1si \u00fctemterv<\/h2>\n<div style=\"overflow-x:auto;margin:18px 0;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:14px;\">\n<thead>\n<tr>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Time-point<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Investigation<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Reason<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Alapvizsg\u00e1lat<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Eye exam (fundus + OCT + visual field), FBC, U&#038;E, LFTs, glucose, weight<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Establish retinal baseline + dose-by-actual-weight calculation + screen contraindications.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Months 1\u20136<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Symptom review at each clinical contact<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">GI tolerance, headache, mood, skin rash, muscle weakness.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Year 1, then annually<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">FBC + LFTs<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Rare cytopenias and rare hepatotoxicity.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Year 5, then annually<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Comprehensive ophthalmology screening (OCT + 10-2 visual field + fundus autofluorescence)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Detect early retinopathy before irreversible damage.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Symptom-driven<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">CK + EMG if proximal weakness; nerve conduction if neuropathic symptoms<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Rare myopathy \/ neuromyopathy with long-term use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Mell\u00e9khat\u00e1sok<\/h2>\n<ul>\n<li><strong>Common (5\u201315 %):<\/strong> nausea, diarrhoea, abdominal cramping (mitigated by taking with food), headache, dizziness, mild itching, skin pigmentation (slate-grey patches in long-term users).<\/li>\n<li><strong>Less common (1\u20135 %):<\/strong> hair lightening, photosensitivity, mood change, vivid dreams, blurred vision (early reversible accommodation effect \u2014 distinct from late retinopathy), tinnitus.<\/li>\n<li><strong>Ritka, de s\u00falyos:<\/strong> retinopathy (long-term, dose-dependent \u2014 see red-box), cardiomyopathy \/ QT prolongation (especially with concurrent QT-prolongers), myopathy, neuromyopathy, agranulocytosis, severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, AGEP, drug rash with eosinophilia and systemic symptoms \/ DRESS).<\/li>\n<li><strong>Sz\u00edvrendszer:<\/strong> QTc prolongation is dose-dependent. Avoid combination with other QT-prolonging drugs (azithromycin, fluoroquinolones, ondansetron, methadone, antipsychotics) and correct electrolyte imbalance before high-dose therapy.<\/li>\n<\/ul>\n<h2>Gy\u00f3gyszerk\u00f6lcs\u00f6nhat\u00e1sok<\/h2>\n<div style=\"overflow-x:auto;margin:18px 0;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:14px;\">\n<thead>\n<tr>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">K\u00f6lcs\u00f6nhat\u00e1s<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Hat\u00e1s<\/th>\n<th style=\"background:#2c7cb0;color:#fff;padding:8px;text-align:left;\">Kezel\u00e9s<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Digoxin<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Hydroxychloroquine raises digoxin level<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Monitor digoxin level; halve digoxin dose if needed.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Insulin \/ sulfonylureas \/ metformin<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Hydroxychloroquine improves insulin sensitivity \u2192 hypoglycaemia risk<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Monitor blood glucose; reduce diabetic medication dose if symptomatic hypoglycaemia.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Metotrex\u00e1t<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">No significant pharmacokinetic interaction; combined as standard csDMARD pair<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Combination is standard rheumatology practice.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">QT-prolonging drugs (azithromycin, ondansetron, fluoroquinolones, methadone, antipsychotics)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Additive QTc prolongation<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Avoid co-administration in patients with structural heart disease, electrolyte disturbance, or pre-existing long QT.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Ciklosporin<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Hydroxychloroquine raises cyclosporine level<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Monitor cyclosporine level if combined.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Antacids (Mg \/ Al hydroxide)<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Reduce hydroxychloroquine absorption ~ 30 %<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Separate by 4 hours.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Mefloquine<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Both can lower seizure threshold<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Avoid combination; choose one antimalarial agent.<\/td>\n<\/tr>\n<tr style=\"\">\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Tamoxifen<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Synergistic retinal toxicity in long-term use<\/td>\n<td style=\"padding:8px;border-top:1px solid #e0e0e0;vertical-align:top;\">Use lowest effective dose; intensified ophthalmology screening.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Ellenjavallatok \u00e9s \u00f3vint\u00e9zked\u00e9sek<\/h2>\n<ul>\n<li><strong>Absolute:<\/strong> known hypersensitivity to 4-aminoquinolines; pre-existing retinopathy.<\/li>\n<li><strong>\u00d3vatosan:<\/strong> renal impairment (dose by actual body weight; consider dose reduction at CrCl &lt; 30 mL\/min), hepatic impairment, history of psoriasis (can flare), porphyria (can precipitate attack), G6PD deficiency, severe GI disease, neurological disease (rare seizures), psoriasis (flare risk).<\/li>\n<li><strong>Terhess\u00e9g:<\/strong> compatible. Continuing hydroxychloroquine during pregnancy in lupus reduces flares and improves outcomes; ACR \/ EULAR \/ British Society for Rheumatology all recommend continuation. Crosses placenta \u2014 neonatal retina is not affected at maternal therapeutic dose.<\/li>\n<li><strong>Szoptat\u00e1s:<\/strong> compatible. Excreted in breast milk in tiny amounts.<\/li>\n<\/ul>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.6;\"><strong>COVID-19 evidence note.<\/strong> Multiple high-quality randomised controlled trials (RECOVERY, SOLIDARITY, ORCHID, COVID-OUT, OVCH-19) have shown hydroxychloroquine does NOT reduce mortality, hospitalisation, or progression of COVID-19. The drug is not recommended for COVID-19 prophylaxis or treatment. Hqcheal is a malaria + autoimmune-disease medication only.<\/div>\n<h2>T\u00e1rol\u00e1s<\/h2>\n<p>Store below 25 \u00b0C in a dry place, in original packaging. Keep out of reach of children \u2014 paediatric overdose with a single 200 mg tablet has caused fatal cardiotoxicity in a small child.<\/p>\n<h2 id=\"faqs\">Gyakran Ism\u00e9telt K\u00e9rd\u00e9sek<\/h2>\n<h3>How long does Hqcheal take to work for rheumatoid arthritis or lupus?<\/h3>\n<p>Most patients notice meaningful improvement at 8\u201312 weeks; the benefit continues to deepen for 6 months. Do not stop early because of &#8220;no effect at 4 weeks&#8221;. Combination with methotrexate may be used for faster onset in higher-disease-activity rheumatoid arthritis.<\/p>\n<h3>Do I need an eye exam before starting?<\/h3>\n<p>Yes \u2014 baseline fundus + OCT + visual field. Annual screening from year 5 of continuous use, earlier if dose &gt; 5 mg\/kg\/day actual weight, renal CrCl &lt; 60, or concurrent tamoxifen.<\/p>\n<h3>Can I take Hqcheal for malaria prophylaxis on a Southeast Asia or Africa trip?<\/h3>\n<p>No. Most modern endemic regions have widespread chloroquine and hydroxychloroquine resistance. Use mefloquine, doxycycline, or atovaquone-proguanil. Speak to a travel-medicine clinic for destination-specific advice.<\/p>\n<h3>What dose should I take for autoimmune disease?<\/h3>\n<p>Long-term maintenance should not exceed 5 mg\/kg\/day of actual body weight (not ideal body weight). For most adults this works out at 200\u2013400 mg\/day. Higher doses raise the retinal-toxicity risk substantially.<\/p>\n<h3>Biztons\u00e1gos terhess\u00e9g alatt?<\/h3>\n<p>Yes. Continuing hydroxychloroquine during pregnancy in lupus reduces disease flares and adverse pregnancy outcomes. Stopping it in pregnancy is associated with increased lupus flare and worse maternal and foetal outcomes.<\/p>\n<h3>Ihatok alkoholt?<\/h3>\n<p>Moderate alcohol is acceptable. Avoid heavy drinking \u2014 both alcohol and hydroxychloroquine can rarely cause hepatotoxicity, and the combination raises the cardiac QT signal slightly.<\/p>\n<h3>Why does the doctor want a baseline weight?<\/h3>\n<p>The 5 mg\/kg\/day cap is calculated on actual body weight, not ideal body weight. Patients above ~80 kg often need 400 mg\/day; patients below ~50 kg often need 200 mg\/day to stay below the retinal-toxicity threshold.<\/p>\n<h3>Mi a teend\u0151, ha kihagyok egy adagot?<\/h3>\n<p>Take it as soon as you remember unless it is close to the next dose. Do not double up. The 40-day half-life means a single missed dose has a tiny effect on overall blood levels.<\/p>\n<h3>Does Hqcheal cause weight gain?<\/h3>\n<p>No. Hydroxychloroquine is weight-neutral and slightly improves insulin sensitivity in patients with type 2 diabetes.<\/p>\n<h3>Is hydroxychloroquine the same as chloroquine?<\/h3>\n<p>Closely related but not identical. Hydroxychloroquine has an extra hydroxyl group that gives it a substantially better retinal-toxicity profile (~ 40 % less retinotoxic at equivalent doses) and better tolerability. For autoimmune disease, hydroxychloroquine is preferred over chloroquine. For malaria treatment in chloroquine-sensitive areas, both work.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Malaria Tablets<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/hu\/hcqs\/\"><strong>HCQS 200\/400 mg<\/strong><\/a> \u2014 Cipla hydroxychloroquine \u2014 200 mg and 400 mg strengths<\/li>\n<li><a href=\"https:\/\/medsbase.com\/hu\/hqtor\/\"><strong>Hqtor 200 mg<\/strong><\/a> \u2014 Torrent Pharma hydroxychloroquine 200 mg<\/li>\n<li><a href=\"https:\/\/medsbase.com\/hu\/hyquin\/\"><strong>Hyquin 200 mg<\/strong><\/a> \u2014 Hetero hydroxychloroquine 200 mg<\/li>\n<li><a href=\"https:\/\/medsbase.com\/hu\/lariago\/\"><strong>Lariago 250 mg<\/strong><\/a> \u2014 Chloroquine \u2014 older 4-aminoquinoline, malaria-only use in chloroquine-sensitive areas<\/li>\n<li><a href=\"https:\/\/medsbase.com\/hu\/mefque\/\"><strong>Mefque 250 mg<\/strong><\/a> \u2014 Mefloquine \u2014 once-weekly chemoprophylaxis for chloroquine-resistant areas<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;font-size:13px;line-height:1.6;\"><strong>Orvosi nyilatkozat.<\/strong> This page is general information only and is not a substitute for travel-medicine advice or treatment under a clinician. Destination-specific drug-resistance patterns change \u2014 confirm prophylaxis choice against current <a href=\"https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/preparing\/malaria\" rel=\"nofollow noopener\" target=\"_blank\">CDC Yellow Book<\/a> vagy <a href=\"https:\/\/www.fitfortravel.nhs.uk\/destinations\" rel=\"nofollow noopener\" target=\"_blank\">fitfortravel.nhs.uk<\/a> guidance before travel. Any febrile illness within 1 year of travel to a malaria-endemic area warrants urgent thick-and-thin blood film. Severe malaria (impaired consciousness, jaundice, hypoglycaemia, respiratory distress) is a hospital emergency.<\/div>","protected":false},"excerpt":{"rendered":"<p>\u2705 Autoimmun betegs\u00e9gek kezel\u00e9s\u00e9re<br \/>\n\u2705 Manages malaria effectively<br \/>\n\u2705 Gyorsan cs\u00f6kkenti a gyullad\u00e1st<br \/>\n\u2705 Alleviates rheumatoid arthritis symptoms<br \/>\n\u2705 Helps with lupus symptoms<\/p>\n<p>Hqcheal contains <strong>Hydroxychloroquine<\/strong>.<\/p>","protected":false},"featured_media":57537,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3580,3448],"product_tag":[5301,4321,4314],"class_list":{"0":"post-57536","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-malaria-tablets","8":"product_cat-travel-health-category-overview","9":"product_tag-hcq","10":"product_tag-hqcheal","11":"product_tag-hydroxychloroquine","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product\/57536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/comments?post=57536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media\/57537"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media?parent=57536"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_brand?post=57536"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat?post=57536"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_tag?post=57536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}